Back to Search
Start Over
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.
- Source :
- Clinical & Translational Oncology; Jun2021, Vol. 23 Issue 6, p1003-1019, 17p
- Publication Year :
- 2021
-
Abstract
- CAR-T cell therapy, as a novel immunotherapy approach, has indicated successful results in the treatment of hematological malignancies; however, distinct results have been achieved regarding solid tumors. Tumor immunosuppressive microenvironment has been identified as the most critical barrier in CAR-T cell therapy of solid tumors. Developing novel strategies to augment the safety and efficacy of CAR-T cells could be useful to overcome the solid tumor hurdles. Similar to other cancer treatments, CAR-T cell therapy can cause some side effects, which can disturb the healthy tissues. In the current review, we will discuss the practical breakthroughs in CAR-T cell therapy using the multi-targeted and programmable CARs instead of conventional types. These superior types of CAR-T cells have been developed to increase the function and safety of T cells in a controllable manner, which would diminish the incidence of relevant side effects. Moreover, we will describe the capability of these powerful CARs in targeting multiple tumor antigens, redirecting the CAR-T cells to specific target cells, incrementing the safety of CARs, and other advantages that lead to promising outcomes in cancer CAR-T cell therapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1699048X
- Volume :
- 23
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Clinical & Translational Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 150062858
- Full Text :
- https://doi.org/10.1007/s12094-020-02490-9